ENGN vs SIF Comparison

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.